EL PASO, TX--(Marketwired - Nov 16, 2016) - Premier Biomedical, Inc. (OTCQB: BIEI) a biotechnology R&D public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as non-narcotic, all-natural-ingredient, 50-state legal, novel pain management therapies, announced today the early results from users of their pain patch samples. Patients who have been given the patch have reported significant or complete relief of their pain for multiple-days with no reported side-effects. Here is just a sample of their results in their own words.
The husband of a patient, who suffers from chronic jaw pain and migraines, but has not experienced relief through conventional pain relief medications, including opioids, reported that the Premier Biomedical Pain Management Solutions pain patch "helped alleviate her pain, and allowed her to reduce her dosage of these other pain medications."
Another patient writes, "I have chronic hip pain and I have a difficult time sleeping through the night because of the pain. A friend recommended that I try the Premier CBD patch. I was skeptical at first, but said that I would try it. I placed the patch on my hip before I went to bed. To my surprise, I woke up in the morning completely rested. I was not stiff or sore. The hip pain was gone for almost two days with one patch."
An Emergency Medicine physician suffering from spinal stenosis-induced low back pain, who has tried various other treatments, including opioids, reported moderate relief within 45 minutes, and complete relief within 90 minutes. This relief lasted for three days. She was so impressed with the results, she is looking forward to having the patch available for the many patients she sees in her practice.
And, from a former nurse and wife of a medical doctor, "The Premier Biomedical pain patches are phenomenal! Having a failed back surgery many years ago, which left me with chronic pain and early retirement from a nursing career I loved, I tried a variety of medications and therapies, none of which have helped me as much as the (Premier Biomedical pain relief) patch. These have been a huge relief for me and quiet my pain down to a very comfortable level."
(While these are typical results from our users, individual results vary, and are not guaranteed to work in all individuals on all types of pain.)
William A. Hartman, President and CEO of Premier Biomedical, stated, "We are very encouraged by this early feedback on the quality of life improvement our participants have experienced. This confirms our own internal studies and previous anecdotal information on the safety and efficacy of our product. Our pain relieving patch provides relief for up to 96-hours versus competitive 6-12-hour patches. We intend to launch our pain relieving patch in just a few weeks, in early January, 2017. We expect to introduce product variants throughout 2017, such as roll-on, cream, spray, lip balm and capsule forms, based on the same active ingredients as our pain relieving patch."
Ronald T. LaBorde, Managing Director of Premier's Pain Management Solutions Joint Venture, said, "The extended relief and durability of our reservoir patch design are a tremendous improvement over other skin patches. As our users are reporting, they are able to reduce their other pain medications, including opioids, which have numerous negative side-effects associated with them. The convenience and effectiveness that are being reported are important advantages over competitive products."
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans, focusing on two major areas - 1) Biologics and Extracorporeal Treatments; and 2) Non-narcotic Pain Management Products. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending patents and provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.